AAV Gene Therapy's Achilles' Heel 'Immune Toxicity' Overcome by Precise Management
-
The promise of gene therapy and unexpected pitfalls The AAV vector has sparked a revolution in the treatment of numerous genetic diseases due to its high delivery efficiency. However, contrary to the rosy outlook of preclinical stages, clinical trials in actual patients have reported life‑threatening adverse reactions, elevating safety management to the top priority.
-
Major red flags in the clinical setting: immune toxicity syndromes The paper summarizes the serious immune‑related syndromes that can occur after AAV administration as follows:
- Systemic reactions: cytokine storm, hemophagocytic lymphohistiocytosis (HLH)
- Organ‑specific toxicities: hepatotoxicity, myocarditis, acute respiratory distress syndrome (ARDS)
- Vascular and hematologic: thrombotic microangiopathy (TMA)
- The root of toxicity: why does the body attack AAV? These adverse events are not merely drug toxicity but the result of the body's complex immune network.
- Capsid and transgene: both the viral capsid and the therapeutic genetic payload inside it become targets of innate and adaptive immunity.
- Interference from pre‑existing immunity: if a patient has previously been exposed to a similar virus and harbors antibodies (pre‑existing immunity), the immune response becomes more vigorous.
- Three key mitigation strategies for successful trials The authors emphasize that the outcome of a clinical trial hinges on the following ‘immune‑modulation protocol’:
- Precise pre‑screening: assess patients for pre‑existing antibodies before dosing to identify high‑risk individuals.
- Optimal dose selection: find a balance that maintains therapeutic efficacy while avoiding undue stimulation of the immune system.
- Administration of potent immunomodulators: use steroids or other immunosuppressants prophylactically or in combination to pre‑empt excessive immune reactions.
- Outlook: next‑generation gene therapies underpinned by safety This review demonstrates that gene therapy is moving from an era of ‘simple delivery’ to one of ‘precise management.’ Toxicity‑management strategies grounded in immunological insight not only safeguard patient safety but also provide a solid foundation for next‑generation gene therapies to achieve market adoption.
Gene therapy using recombinant adeno-associated virus (rAAV) vectors has emerged as a transformative therapeutic modality for genetic disorders, demonstrating high transduction efficiency and a generally favorable safety profile during pre-clinical development. However, serious adverse events, including thrombotic microangiopathy, acute respiratory distress syndrome, hepatotoxicity, myocarditis, cytokine storm, and hemophagocytic lymphohistiocytosis, have been observed across multiple gene therapy clinical trials. Significant efforts have been made to understand the toxicities that cause these adverse events and clinical care for patients receiving gene therapies has evolved to mitigate their effects. These toxicities arise from a complex interplay between the innate and adaptive immune responses directed against the viral capsid and transgene products and are often compounded by pre-existing anti-AAV immunity. Immunomodulatory strategies have been developed to combat these responses to improve the long-term success of gene therapies, and this review provides clinicians managing gene therapy patients with an overview of mechanisms underlying AAV-associated immunotoxicities and a discussion of syndromes and mitigation strategies that have been reported in the clinical care of patients.
Immune toxicity threatens the safety of gene therapy, posing significant risks to patients and society. Understanding and managing it is essential for expanding therapeutic access and building trust.